– Invitae to report on secondary patient data use, demonstrating real-world impact of de-identified patient data on the advancement of precision medicine –
– Company achieves over 1 million ClinVar submissions to advance science and patient care –
SAN FRANCISCO, Dec. 7, 2022 /PRNewswire/ — Invite (NYSE: NVTA), a leading medical genetics company, today announced the release of its Data Use Transparency and Impact Report, which details how the company has used de-identified patient data to advance precision medicine. While many companies collect patient data, they do not disclose how this data is being used. Invitae is leading the industry by publishing this first-of-its-kind report on how it used de-identified patient data for secondary data research in 2021.
Unlike most companies, Invitae offers patients a choice on whether or not to allow access to their de-identified data for research. As a company grounded in the principles that patients own and control their data and that data is more valuable when shared, this report demonstrates how Invitae delivers on those principles in a way that honors the intent of patients with the ultimate goal of advancing the science of genomics and precision medicine.
“For precision medicine to advance and real-world evidence to matter, patients must be able to trust that the companies accessing and sharing their data are only working with trustworthy partners who are equally committed to advancing science,” said Deven McGraw, lead of data stewardship and data sharing at Invitae. “Being transparent about how we use data is essential to not only earning that trust but also to demonstrating the impact that patients can have on advancing science and medicine by sharing access to their data.”
McGraw continued, “It’s time for all companies that generate, collect, use and share de-identified patient data to let patients know how their data is being used and see the impact they are having. In a culture of diminishing trust, transparency is no longer an option. It’s essential.”
With a database of more than 2 million tested individuals around the world which is available for researchers to access such individuals’ de-identified data, Invitae’s research is critical to understanding the prevalence of gene changes responsible for a wide array of hereditary diseases, developing new treatments and identifying people who could benefit from targeted, precision therapies. In 2021, patient data enabled the company to advance important research initiatives and achieve the following:
- Improving Internal Processes and Testing Quality: Invitae uses the data generated by genetic testing to confirm our tests meet applicable quality and validity standards, to ensure our products improve, and to advance the science of genetic testing.
- Advancing the Science of Genetics: De-identified data from certain individuals tested by Invitae informed an array of research across medical conditions, including contributions to 38 peer-reviewed publications across 10 health areas, 36 posters covering 11 health topics and 21 abstracts as part of the proceedings of more than 22 scientific symposium.
- Advancing the Development of New Treatments:
To help accelerate access to testing and the development and use of genetic-informed therapies, Invite offered “sponsored” testing programs in which patients agree to allow biopharma companies to access their de-identified data obtained through no charge genetic testing. In 2021, Invite worked with 31 biopharma companies to offer 47 sponsored testing programs. In addition, Invite worked with 15 biopharma partners to conduct clinical trial outreach initiatives covering 17 medical conditions.
- Advancing Science-Driven Policy: Based on analysis of its test data, Invitae developed educational materials and distributed them to policymakers considering the development of legislation to expand access to pediatric genetic testing.
A New Milestone for Open Data
Further showcasing the importance of sharing patient data, Invite recently reached a milestone of more than 1 million ClinVar submissions. ClinVar is a National Institutes of Health database of genetic variants that serves as a global resource for sharing interpretations of different genetic variants. ClinVar enables testing labs and researchers to compare findings, helping to expand the collective understanding of each variant. As the leading contributor to this database, Invite views this milestone as a testament to the company’s founding principle that genetic data is more valuable when it’s shared. Currently, Invite has contributed more variants than the next 16 largest contributors to ClinVar combined.
“Patients need the science of genetics to advance as rapidly as possible,” said McGraw. “For that to happen, scientists need to share the data that informs their interpretation with their peers. This milestone shows we are committed to advancing the role that genetic understanding can play in helping patients who need treatments and cures.”
“This first-of-its-kind report is an important first step towards transparency, and it’s something that should be standard practice for the genetic diagnostic industry as a whole,” said Andrea Downing, co-founder of The Light Collective. “Invitae is making important strides to lead the industry in accountability to patient communities.”
To learn more, you can download the full report TIMES.
Invite Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae’s goal is to aggregate the world’s genetic tests into a single service with higher quality, faster turnaround time and lower prices. For more information, visit the company’s website at invitee.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s belief that it is leading the industry by publishing a first-of-its-kind report on how it used de – identified, patient data for secondary data research; the company’s beliefs regarding the importance of this report and transparency regarding data use; and the benefits of the company’s research and use of de-identified patient data. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company’s history of losses; the company’s ability to compete; the company’s failure to manage growth effectively; the company’s need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company’s ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company’s business; and the other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. These forward-looking statements speak only as of the date hereof, and Invite Corporation disclaims any obligation to update these forward-looking statements.
SOURCE Invitae Corporation